Phase 2a Proof-of-Concept, Multicenter, Randomized, Open Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Dose of the Combination M5717-pyronaridine as Chemoprevention in Asymptomatic Adults and Adolescents With Plasmodium Falciparum Malaria Infection (CAPTURE-2)

This study will evaluate the efficacy and safety of a single dose of M5717 plus pyronaridine tetraphosphate in clearing current Plasmodium falciparum infection and protecting against recurrent infections in asymptomatic adults and adolescents. The study will also assess the duration of protection provided by different doses of M5717 plus pyronaridine and the additional contribution of M5717 to the duration of protection using external study data.

开始日期2023-11-28

申办/合作机构

Merck Healthcare KGaA

ChiCTR2400081377

/ Not yet recruiting临床3期IIT

A multicenter, open, parallel, randomized controlled clinical trial comparing the safety and efficacy of Jinghua Shikang MPA-01 foldable posterior chamber hydrophobic aspheric intraocular lens and Johnson vision care foldable posterior chamber acrylic intraocular lens

开始日期2023-09-01

申办/合作机构

北京协和医院

[+1]

PACTR202402599048090

/ Unknown status临床2期IIT

Efficacy and safety of pyronaridine/artesunate and pyronaridine/artesunate/praziquantel for treatment of uncomplicated Schistosoma haematobium infection in Gabonese adolescents and children

开始日期2023-09-01

申办/合作机构-

100 项与磷酸咯萘啶相关的临床结果

登录后查看更多信息

100 项与磷酸咯萘啶相关的转化医学

登录后查看更多信息

100 项与磷酸咯萘啶相关的专利（医药）

登录后查看更多信息

431

项与磷酸咯萘啶相关的文献（医药）

2026-01-21·JOURNAL OF CHEMICAL PHYSICS

Physical–chemical approach to identify local structural determinants of molecular mechanisms: Case study of antimalarial drug pyronaridine and crystal-growth inhibition

Article

作者: Medvedeva, Angela ; Kolomeisky, Ksenia ; Kolomeisky, Anatoly B.

Understanding how specific molecular substructures control chemical behavior is central to rational molecular design and the development of new materials. However, most current predictive models offer limited mechanistic resolution at the fragmental level. We present a conceptually novel use of fragment-based structure–activity reasoning, based on systematically perturbing a parent molecule, to quantify fragment-level contributions to both a specific mechanistic action and a broader functional outcome. As a case study, we investigated local structural contributions to pyronaridine (PY), a clinically used antimalarial drug with a mechanistically distinctive mode of inhibition of hematin crystal growth via step-bunching. Chemically plausible PY molecular analogs have been computationally generated by selectively removing or substituting functional groups hypothesized to influence either step-bunching mechanisms or whole-parasite blood-stage activity. For each analog, we predicted the probability of four different crystal-growth inhibition mechanisms using a centroid-based similarity model based on a small dataset of experimentally verified crystal-growth inhibitors. The blood-stage antimalarial activity has also been estimated using the MAIP platform. A systematic comparison of molecular analogs revealed that step-bunching mechanisms depend primarily on two protonated pyrrolidines, with chlorobenzene as a strong secondary contributor. In contrast, antimalarial activity is more distributed, relying on coordinated interactions between aromatic–heteroatom scaffolds and an amine linker. The obtained results demonstrate that our approach can disentangle position-specific and cooperative fragmental effects, offering mechanistically interpretable guidance for the design of mechanism-optimized inhibitors. The framework might be broadly applicable across chemical and materials domains where linking local structure to specific mechanisms is essential.

2026-01-01·EClinicalMedicine

Artemether-lumefantrine versus pyronaridine-artesunate for the treatment of malaria in patients with mild to moderate COVID-19 in Kenya and Burkina Faso: a randomised open-label trial (MALCOV)

Article

作者: Marlais, Tegwen ; Ouedraogo, Alphonse ; Wu, William ; Allen, David J ; Hannan, Luke ; Otieno, Kephas ; Drabko, Anna ; Odawo, Telesphorus ; Achieng, Morine ; Drakeley, Chris ; Ter Kuile, Feiko O ; Soulama, Ben I ; Kariuki, Simon ; Canizales, Jennifer ; Soulama, Issiaka ; Brazal-Monzó, Helena ; Kabore, Jean Moise T ; Onyango, Eric D ; Tangara, Brian ; Barsosio, Hellen C ; Wanjiku, Miriam ; Lesosky, Maia ; Serme, Samuel S ; Aura, Henry ; Matthewman, Julian ; Sirima, Sodiomon B ; Barry, Aissata ; Tetteh, Kevin Ka ; Tiono, Alfred B ; Ondieki, Everlyne D ; Badoum, Emilie S

Background:

It is unknown whether the choice of malaria treatment for uncomplicated malaria affects coronavirus disease 2019 (COVID-19) severity, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load, or duration of viral shedding. Several antimalarials exhibit antiviral activity against SARS-CoV-2 in vitro and have been suggested as potential therapeutic candidates for COVID-19, particularly pyronaridine-artesunate (PA), despite disappointing clinical results with chloroquine and hydroxychloroquine.

Methods:

We conducted an open-label randomised trial comparing standard 3-day treatment with PA and artemether-lumefantrine (AL) in newly diagnosed SARS-CoV-2 infected patients aged ≥6 months with rapid diagnostic test or microscopy-confirmed non-severe malaria in Kenya and Burkina Faso. SARS-CoV-2 was assessed by RT-PCR on days 3, 7, 14, and 28, and symptom resolution was assessed daily for 14 days using FLU-PRO Plus. The primary endpoint was the proportion of participants with SARS-CoV-2 clearance by day 7. Secondary endpoints included SARS-CoV-2 clearance by days 14, 21, and 28, time to SARS-CoV-2 clearance over 28 days, median viral load on day 7, and time to symptom resolution. Complete case analysis was conducted using log-binomial regression for binary outcomes, Cox-regression for time-to-event outcomes, and negative binomial regression for count outcomes, all adjusted for disease severity and viral load at enrolment. The trial is registered with ClinicalTrials.gov NCT04695197.

Findings:

From January 2021 to January 2022, 143 participants were randomised (PA = 69, AL = 74, intention-to-treat [ITT] population), including 117 with reverse transcription polymerase chain reaction (RT-PCR) confirmed (PA = 58, AL = 59, modified intention-to-treat [mITT] population) and 26 with rapid-antigen test confirmed SARS-CoV-2 infection. The median age was 19 years (interquartile range [IQR] 13-38), 66% were aged ≥15 years. Baseline characteristics were comparable. SARS-CoV-2 clearance by day 7 (primary endpoint) was 41% (22/54) with PA versus 58% (33/57) with AL (adjusted risk ratio [aRR] = 0.78, 95% confidence interval [CI] 0.45-1.35, p = 0.37); by day-14: PA = 80% (44/55) versus AL = 96% (55/57) (aRR = 0.86, 0.58-1.29, p = 0.47). Median (IQR) viral load on day 7 was higher with PA (855 [30-2883] versus AL:81 [12-209] copies/mL, p = 0.023). Time to SARS-CoV-2 clearance over 28 days was slower with PA (adjusted hazard ratio [aHR]: 0.55, 0.37-0.83, p = 0.004). Time to symptom clearance between treatments was similar (aHR = 1.01, 0.91-1.13, p = 0.79). Parasitological cure rates by day 42 were PA = 100% and AL = 99%. Five serious adverse events occurred (PA = 2, AL = 3) in three participants (PA = 1, AL = 2), including three hospitalisations (PA = 1, AL = 2), resulting in two deaths, both from respiratory failure (PA = 1, AL = 1). No serious adverse events (SAEs) were considered treatment-related.

Interpretation:

Pyronaridine-artesunate in COVID-19 patients co-infected with malaria was associated with slower viral clearance than standard treatment with artemether-lumefantrine but similar symptom resolution. Both treatments were highly effective as antimalarials and should continue to be considered first- or second-line treatment options for uncomplicated malaria in patients with mild to moderate COVID-19.

Funding:

Gates Foundation.

2026-01-01·LANCET INFECTIOUS DISEASES

Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial

Article

作者: Appiah, Grace ; Nsobya, Sam L ; Orena, Stephen ; Opigo, Jimmy ; Kamya, Moses R ; Moriarty, Leah F ; Ebong, Chris ; Agaba, Bosco ; Tukwasibwe, Stephen ; Mugwanya, Edward ; Kyabayinze, Daniel ; Yeka, Adoke ; Nankabirwa, Joaniter I ; Okitwi, Martin ; Rosenthal, Philip J ; Sebikaari, Gloria ; Condo, Patrick M ; Asua, Victor ; Rutazana, Damian ; Binagwa, Benjamin ; Kiggundu, Moses ; Conrad, Melissa D ; Babirye, Shakira

BACKGROUND:

Anti-malarial artemisinin-based combination therapies (ACTs) might be losing efficacy in east Africa, with the spread of artemisinin partial resistance and reduced partner drug activity. Our trial aimed to measure the efficacies of artemether-lumefantrine, artesunate-amodiaquine, dihydroartemisinin-piperaquine, and artesunate-pyronaridine in three sites in Uganda.

METHODS:

This randomised, open-label, phase 4 clinical trial was carried out at three sites in the Agago, Arua, and Busia districts of Uganda. Children aged 6 months to 10 years with uncomplicated Plasmodium falciparum malaria were randomly assigned to receive either artemether-lumefantrine (20 mg artemether; 120 mg lumefantrine; twice a day for 3 days) in all sites or dihydroartemisinin-piperaquine (40 mg dihydroartemisinin and 320 mg piperaquine, once a day for 3 days) in Agago, artesunate-amodiaquine (25 mg artesunate and 67·5 mg amodiaquine for children <9 kg or 50 mg artesunate and 135 mg amodiaquine for children ≥9 kg, once a day for 3 days) in Busia; and artesunate-pyronaridine (60 mg artesunate and 180 mg pyronaridine for children >15 kg or 20 mg artesunate and 60 mg pyronaridine for children <15 kg, once a day for 3 days) in Arua, with follow-up to 42 days. Participants were not blinded to group assignments; however, investigators and those assessing outcome were masked. The primary outcome was parasitaemia, assessed by microscopy, either uncorrected or PCR-corrected to distinguish recrudescence from new infection. All participants who received the treatment per protocol and were not lost to follow-up were included in the primary outcome. All participants who were randomly allocated to treatment groups were included in the safety analyses. This study is registered with the Pan African Clinical Trials Registry, number PACTR202301796134887, and is complete.

FINDINGS:

Between Nov 7, 2022, and March 24, 2023, 808 participants (437 [54%] female) were enrolled and assigned to treatment groups; 15 (2%) were lost to follow-up and 793 (98%) completed follow-up. The uncorrected adequate clinical and parasitological response for artemether-lumefantrine was 87 (51·8%; 95% CI 44·0-59·5) of 168 participants in Arua, 88 (51·8%; 44·0-59·4) of 170 and Busia, and 131 (79·4%; 72·3-85·1) of 165 in Agago. This response for artemether-lumefantrine was lower than that of the other ACTs at all sites: 97 (98·0%; 92·2-99·6) of 99 for dihydroartemisinin-piperaquine in Agago, 95 (99·0%; 93·5-99·9) of 96 for artesunate-amodiaquine in Busia, and 73 (73·7%; 63·8-81·8) of 99 for artesunate-pyronaridine in Arua. PCR-corrected 28-day efficacies were 88 (81·5%; 72·6-88·1) of 108 for artemether-lumefantrine and 95 (100%; 95·2-100·0) of 95 for artesunate-amodiaquine in Busia; 131 (97·0%; 92·1-99·0) of 135 for artemether-lumefantrine and 97 (100%; 95·3-100·0) of 97 for dihydroartemisinin-piperaquine in Agago; and 87 (82·1%; 73·2-88·6) of 106 for artemether-lumefantrine and 73 (92·4%; 83·6-96·9) of 79 for artesunate-pyronaridine in Arua. All regimens were well tolerated. The most common adverse events were upper respiratory tract infection, diarrhoea, and anaemia. None of the reported adverse events were attributed to the study drugs. There were two serious adverse events, both cases of severe malaria in Arua, one in each of the treatment groups. Parasite clearance half-lives were prolonged with parasites carrying the PfK13 Cys469Tyr (median 4·2 h; IQR 3·4-4·9) and Ala675Val (4·9 h; 3·4-5·7) mutations compared with wild-type parasites (2·8 h; 2·3-3·6; p<0·0001).

INTERPRETATION:

Artemether-lumefantrine was associated with a higher risk of recurrent malaria than other antimalarial combinations tested, and K13 mutations were associated with delayed parasite clearance. Changes in first-line therapy for uncomplicated malaria must be considered in response to suboptimal efficacy of artemether-lumefantrine.

FUNDING:

US President's Malaria Initiative, US Agency for International Development, through the Uganda Malaria Reduction Activity and the National Institutes of Health (AI075045 and AI117001).

TRANSLATION:

For the Swahili translation of the abstract see Supplementary Materials section.

项与磷酸咯萘啶相关的新闻（医药）

2026-01-26

·药物分子设计

Nextflow可重复工作流TCGA调控网络分析

背景测序和计算技术的进步已助力深入探索疾病的分子机制。生物网络已被证实是分析多组学数据、建模基因与蛋白质间调控相互作用的宝贵框架。癌症基因组图谱（TCGA）等大型合作项目为开发和验证新计算方法提供了丰富资源，催生了大量用于数据下载、预处理和分析的开源软件。然而，对于调控网络的端到端分析，亟需个连贯且可复用的工作流，将所有相关软件包整合为稳健的分析流程。 johnq@hsph.harvard.edu #基因调控网络 #癌症基因组图谱 #癌症 #Nextflow #NetworkDataCompanion #可重复性 tcga-data-nf Nextflow工作流整合了核心的下载、预处理和分析步骤（如图中央所示），助力用户可重复地生成癌症基因调控网络（GRNs）。通过单一命令行调用和纯文本配置文件，该工作流可生成中间处理文件、基因调控网络及元数据。左侧：工作流输入和输出示例，以及用户可访问的关键资源（用于分析10种常见癌症并复现本文所有结果）。右侧：tcga-data-nf中使用的核心计算资源和方法。开发了R包NetworkDataCompanion，用于便捷地映射和处理下载的数据。数据准备完成后，可结合Network Zoo计算方法（PANDA、DRAGON、ALPACA、LIONESS）进行网络推断。结果开发了基于Nextflow的工作流tcga-data-nf，用户可通过单一命令从TCGA的数千个样本中可重复地推断调控网络。该工作流分为３个主要步骤：（i）下载多组学数据（如RNA测序和甲基化数据）；（ii）预处理数据；（iii）利用Network Zoo工具集分析并推断调控网络模型。该工作流由R包NetworkDataCompanion提供支持，该包是用于管理、映射和过滤TCGA数据的独立函数集合。本文中，展示了该流程如何用于研究表观遗传机制相关的结直肠癌亚型差异。最后，提供了10种最常见癌症类型的预生成网络数据库，可供公众直接访问。多组学部分相关网络揭示结直肠癌亚型差异图1 结直肠癌亚型间的多组学及调控差异（A）所有亚型中转录因子（TF）甲基化与表达的DRAGON部分相关值分布；橙色表示同一转录因子的边值（启动子甲基化与该转录因子表达的相关性），如预期所示，甲基化与表达倾向于负相关；直方图表示标准化后的分布密度（按亚型和组别归一化）；（B）对于跨模态DRAGON边权重（甲基化-表达），去除同一转录因子间的边，选择前200个最强边（平均绝对相关值最高），并按各亚型的相关值进行聚类（平均连锁法、欧氏距离）；有趣的是，A簇和D簇中CMS2和CMS4的边值方向相反；（C）D簇中所有转录因子与Reactome父术语的详细注释；与A簇相比，“免疫系统”和“细胞对刺激的反应”通路在D簇中更集中；此处可明确哪些转录因子注释到每个术语（例如，多个转录因子参与免疫系统通路：BATF、GATA3、NFATC2、NFATC3、TP53）；如预期所示，许多转录因子注释到通用转录通路，TP53几乎注释到所有术语；（D）D簇转录因子的DRAGON关联图，展示CMS2和CMS4中部分相关性的差异；选择属于D 簇的边（粗边），并添加20个其他连接相同转录因子的顶级边（细边），形成连通图；转录因子以节点表示，甲基化相关节点为绿色，表达相关节点为橙色，边值按差异部分相关值进行颜色编码；（E）ALPACA比较CMS2和CMS4的模块1的通路富集分析（过度表达）；展示所有显著通路（校正后P<0.01）；x轴表示模块1与每个通路的重叠程度，点大小取决于校正后P值；点按类别（图中标注）分组，按子类别着色；许多术语与 “免疫系统”（棕色点）和信号通路（蓝色和橙色点）相关；在 “人类疾病” 术语中，多个涉及免疫系统的通路（包括癌症中PD-L1表达和PD-1检查点通路）被富集；（F）按模块性排序的ALPACA模块1中排名前10的转录因子；（G）ALPACA与DRAGON结果的重叠情况；浅灰色表示每个ALPACA模块中映射到DRAGON 的转录因子比例（大多数模块中约为50%）；深灰色表示在CMS2或CMS4亚型中被视为“沉默”的转录因子比例；模块11中，2个转录因子HOXA10和HOXB9在CMS2中存在沉默现象，而在CMS4中无此现象，这2个转录因子已知具有发育相关功能。结论 tcga-data-nf是个完整、灵活且可扩展的框架，能够实现癌症调控网络的可重复推断与分析，填补了当前TCGA数据分析工具领域的空白。详细总结思维导图核心工具设计３大核心模块（支持独立运行，灵活适配不同分析需求）核心资源与可用性参考 Gigascience. 2025 Jan 6:14:giaf126. doi: 10.1093/gigascience/giaf126. Reproducible processing of TCGA regulatory networks 251020tcga-data-nf.pdf 注：AI辅助创作，如有错误欢迎指出。内容仅供参考，不构成任何建议。

2026-01-21

·汇佳生物

Pentixapharm 获美国 FDA 关于高血压III期诊断性研究反馈

●FDA出具的正式书面会议纪要确认，针对Ga-68 PentixaFor 用于难治性高血压及原发性醛固酮增多症的 Ⅲ 期 PANDA 计划研究，未发现重大问题。 ●B 类临床研究申请前（pre-IND）会议就关键统计学及方法学要点给出非约束性指导意见，助力优化 Ⅲ 期研究设计。 ●此次反馈明确了潜在获批路径对应的证据要求，为该公司核心研发项目—— 靶向 CXCR4 的旗舰产品的临床试验申请（IND）申报提供支持。专注于创新放射性药物研发的临床阶段生物科技公司 Pentixapharm Holding AG（Frankfurt主板市场：PTP）近日宣布，公司已收到美国食品药品监督管理局（FDA）就其靶向 CXCR4 的旗舰产品Ga-68 - PentixaFor 开展的 Ⅲ 期 PANDA 计划研究的科学咨询会议正式书面纪要。PANDA 研究旨在评估这款放射性诊断药物能否成为优化难治性高血压与原发性醛固酮增多症（PA）患者诊断流程的新型工具。借助Ga-68 - PentixaFor PET/CT成像实现疾病分型，有望为患者匹配更适宜的治疗方案，助力制定更精准有效的治疗决策。 FDA 出具的会议纪要进一步明确了计划开展的 Ⅲ 期研究在统计学、方法学以及诊断效能评估标准等方面的多项关键要点，并在 2025 年 12 月 3 日披露的初步会议反馈基础上进行补充说明。 Pentixapharm 首席执行官兼首席医疗官 Dirk Pleimes 博士表示：“FDA 的正式书面反馈，为我们Ga-68 - PentixaFor Ⅲ 期 PANDA 计划研究的关键设计与分析要素提供了明确指导，同时确认研究不存在重大问题。尤为重要的是，反馈还就潜在获批所需的证据要求给出建议，包括单项 Ⅲ 期研究联合验证性证据的应用方式。该指导意见为我们推进IND申报提供了有力支撑，也将进一步助力开发一款具有可推广性的无创诊断工具，用于原发性醛固酮增多症患者的诊疗。原发性醛固酮增多症是继发性高血压最常见的诱因，目前仍存在较高的漏诊率。” 关于Ga-68 - PentixaFor 在难治性高血压与原发性醛固酮增多症中的应用 Ga-68 - PentixaFor 是一款新型放射性诊断药物，有望成为同类首创产品。该药物以Ga-68标记，可选择性靶向趋化因子受体 CXCR4，通过高分辨率 PET/CT 成像实现受体表达的可视化检测。目前，已有超过 100 篇科研文献记录了Ga-68 - PentixaFor PET/CT 在 2600 余例多适应症患者中的临床应用数据，其中原发性醛固酮增多症患者超 1600 例。已发表研究及在研项目均表明，这款诊断药物可实现 CXCR4 表达的稳定在体成像，且安全性良好。近期研究显示，在原发性醛固酮增多症单侧病变特征性的醛固酮分泌型肾上腺肿瘤中，CXCR4 存在高表达现象。原发性醛固酮增多症是继发性高血压的常见诱因，但长期以来漏诊率居高不下，主要原因在于现有诊断工具难以可靠区分单侧与双侧病变类型。单侧病变通常采用手术切除病变肾上腺的治疗方案，而双侧病变则需终身药物治疗。通过对醛固酮分泌组织中 CXCR4 表达水平的可视化检测，Ga-68 - PentixaFor 有望为原发性醛固酮增多症提供更可靠的分型依据，进而优化治疗决策。关于 Pentixapharm Pentixapharm 是一家处于临床阶段的生物科技公司，致力于拓展放射性药物的应用边界。公司总部位于德国柏林，聚焦肿瘤学与心脏病学领域，研发精准诊断与治疗药物，推动患者诊疗模式变革。其临床管线以靶向 CXCR4 的 PET-CT 研发项目为核心，包括一款即将开展 Ⅲ 期研究的候选药物，用于优化原发性醛固酮增多症高血压患者的诊断流程，实现对高血压病因的靶向治疗。基于 CXCR4 靶点的研发项目还涵盖血液肿瘤领域的开创性治疗方案。此外，Pentixapharm 正在推进新一代靶向 CD24 的抗体药物研发平台，CD24 是一种在多种难治性肿瘤中高表达的新兴免疫检查点标志物。依托 CXCR4 与 CD24 相关知识产权保护，以及稳定的同位素供应链，Pentixapharm 有望在精准医疗这一高速发展领域，为患者带来切实获益，同时实现公司的可持续增长。往期回顾 Pentixapharm推进放射性诊断候选药物Ga-68 PentixaFor用于高血压的Ⅲ期PANDA研究相关注册准备工作 Pentixapharm宣布在急性髓系白血病试验中将PentixaTher的用药剂量提高到第四水平 Pentixapharm宣布同类首创的多聚糖依赖性抗CD24单克隆抗体放射性药物GT-008令人鼓舞的临床前数据汇佳生物专注于转化医学领域的前沿研究及临床转化应用技术，业务涵盖生物标志物和药物靶标技术，新型诊断试剂及治疗药物的研发，相关仪器设备的开发及临床转化技术的应用，实现了产、医、研的融合发展。媒体合作/科研宣传/产品咨询长按二维码，联系我们

临床3期放射疗法临床申请

2026-01-14

·腾讯网

今日药闻 | 重磅交易、临床突破与全球合作新动态

1、人民日报整版刊发钟才文文章：深刻把握“五个必须”推动“十五五”良好开局该文章系统阐释了习近平经济思想中“五个必须”的核心内涵，即充分挖掘经济潜能、政策支持与改革创新并举、“放得活”与“管得好”结合、投资于物与投资于人紧密结合、以苦练内功应对外部挑战。文章强调，“十五五”时期是夯实中国式现代化基础的关键阶段，需通过深化内需潜力、科技创新、城乡区域协调等措施，确保经济稳中向好，并在全球竞争中赢得主动。论述突出宏观政策与制度改革的协同性，旨在为高质量发展提供理论指导。2、PF-08634404/SSGJ-707将于2026年开展五项全球多中心III期临床试验三生制药合作伙伴辉瑞宣布，其PD-1/VEGF双抗药物PF-08634404（即SSGJ-707）计划在2026年启动五项全球III期临床试验，覆盖非小细胞肺癌、结直肠癌、子宫内膜癌及尿路上皮癌等适应症。该药物由三生制药基于CLF2平台开发，2025年授权辉瑞全球商业化权利。此举标志着中国创新药国际化步伐加速，双抗技术有望填补肿瘤联合疗法空白。3、56亿美元！荣昌生物PD-1/VEGF双抗授权艾伯维荣昌生物将其PD-1/VEGF双抗RC148以大中华区以外权益授权给艾伯维，协议首付款6.5亿美元，潜在里程碑金额49.5亿美元，另加销售分成。RC148通过同步抑制免疫检查点和血管生成通路增强抗肿瘤活性，目前正在中国开展晚期实体瘤临床研究。此次合作凸显国际药企对中国双抗技术平台的认可，亦反映本土创新药出海模式的成熟。4、16.65亿美元！赛神医药临床前Aβ抗体授权给诺华赛神医药将其临床前阶段透脑Aβ抗体授权给诺华，诺华支付1.65亿美元预付款及15亿美元里程碑金额。该抗体基于赛神专有的血脑屏障穿梭技术（BBBShuttle），旨在提升阿尔茨海默病治疗药物的脑部递送效率。合作涵盖早期临床开发，由诺华主导后期商业化。交易体现中国CNS领域创新技术平台的国际吸引力。5、JPM年会数字健康企业：占比不足5%，但却能看出下一轮定价逻辑与增长路径第44届JPM医疗健康年会中，数字健康企业仅占3.7%，但趋势显示行业从功能叙事转向结果核验。重点企业如Abridge（临床文书生成）、Lyric.ai（支付理赔优化）、Teladoc（远程医疗）等，均聚焦医生工作效率提升、支付方成本控制及患者可及性。分析指出，成功关键在于将价值量化（如减少拒付率、缩短回款周期），并嵌入现有医疗体系合规框架。6、复宏汉霖第五款在美申报上市产品汉贝泰®BLA获受理复宏汉霖宣布其贝伐珠单抗生物类似药汉贝泰®获FDA受理BLA，拟用于结直肠癌、肺癌等多类实体瘤。此前公司已有四款产品（如曲妥珠单抗、地舒单抗类似药）在美获批。汉贝泰®基于药学相似性及I/III期临床数据证明与原研药高度一致。同时，公司正推进其与PD-1单抗H药联合疗法及眼科适应症开发，体现国际化注册与质量管理能力。7、微软研报称DeepSeek在中国AI市场份额达89%微软总裁布拉德·史密斯表示，中国凭借低成本开源模型（如DeepSeekR1）及政府补贴，在非西方市场快速扩张。DeepSeek在埃塞俄比亚、白俄罗斯等国份额达17%-56%，但在全球南方国家AI普及率（14%）仍低于北方（25%）。史密斯警告AI鸿沟可能加剧经济差距，呼吁西方通过政策与资金介入竞争。8、中国生物制药12亿收购赫吉亚，联手小核酸“行业黑马”加速大慢病布局中国生物制药以12亿元全资收购siRNA企业赫吉亚生物，获得其肝内/外递送平台（如MVIP、DDP）及减重、心脑血管、神经领域管线。核心产品Kylo-11为全球首个“一年一针”降Lp(a)药物，已进入中美II期临床。收购旨在补强中国生物制药在心脑血管与代谢疾病领域创新布局，并通过正大天晴商业化能力加速管线落地。9、国家定调！2026最强信号：六大“新兴支柱产业”深度解析全国工信会议明确将集成电路、新型显示、新材料、航空航天、低空经济、生物医药列为六大新兴支柱产业，并启动首批国家示范基地创建。分析指出，此举旨在通过政策资源倾斜突破“卡脖子”环节（如芯片高端制程、航空发动机），同时抢占未来赛道（如eVTOL、生物医药CGT疗法），构建自主可控的现代产业体系。10、5.1亿美元！CRO龙头收购猴子供应商查尔斯河实验室以5.1亿美元收购柬埔寨非人灵长类动物供应商K.F.公司，以强化药物安全性测试关键动物来源控制。K.F.此前占其需求30%，交易完成后将提升供应链自主性。该公司曾因涉嫌猕猴走私被调查，此次收购标志其重建柬埔寨合规供应渠道，亦反映全球临床前CRO对上游资源整合趋势。11、Nature Chemistry：靶向降解再升级马克斯·普朗克研究所团队开发伪天然产物iDegs，可同时抑制IDO1酶活性并诱导其降解。机理研究表明，iDegs通过稳定IDO1脱辅基构象，增强其与天然E3连接酶CRL2KLHDC3结合，促进泛素化降解。该策略克服传统抑制剂仅靶向酶活性的局限，为癌症免疫治疗提供新路径。12、美敦力与脑机接口新势力达成战略合作，正式进军脑机接口美敦力与Precision Neuroscience合作，将其Layer7脑机接口技术（微创薄膜电极阵列）整合至StealthStation手术导航系统，共同开发神经外科解决方案。Layer7具备高密度电极（1024通道）、组织相容性及可逆植入特点，旨在术中提供实时大脑功能信息，提升手术精度。13、和誉医药贝捷迈®新药上市申请获FDA受理，用于治疗腱鞘巨细胞瘤和誉医药CSF-1R抑制剂贝捷迈®（匹米替尼）获FDA受理NDA，基于全球III期MANEUVER研究数据，显示25周时客观缓解率显著优于安慰剂。该药已于2025年12月在中国获批，并由默克负责全球商业化。TGCT为罕见关节肿瘤，贝捷迈®有望填补其口服疗法空白。14、《纽约时报》点赞的AI“医生”，在宁波救了24条生命阿里达摩院胰腺癌检测模型PANDA通过平扫CT早期识别胰腺癌，在宁波大学附属人民医院分析超18万份影像，成功检出24例患者（14例早期）。该模型放大肉眼难辨病灶特征，尤其适用于机会性筛查。尽管存在假阳性挑战，医院仍坚持对中高风险病例随访，体现AI辅助医疗的临床价值。【免责声明】

100 项与磷酸咯萘啶相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	磷酸咯萘啶	P01B	DB12975

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疟疾	-	-	-

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性淋巴细胞白血病	临床2期	肯尼亚	Armaceutica, Inc.	2022-01-30
急性髓性白血病	临床2期	肯尼亚	Armaceutica, Inc.	2022-01-30
埃博拉病毒性疾病	临床前	美国	Collaborations Pharmaceuticals, Inc.	2024-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05287893 (CTgov)	临床1期	虫血症 \| 恶性疟	10	P. falciparum IBSM infection+Pyronaridine (Pyronaridine 360 mg)	遞範鏇壓廠艱壓築鹽願(齋夢廠構廠築觸糧憲願) = 製廠遞衊夢淵艱範夢顧鏇簾淵憲範艱艱糧鬱範 (壓餘鏇遞選艱齋糧蓋醖, 範窪獵遞簾製觸鑰積繭 ~ 襯製築顧簾膚網鹽夢顧) 更多	-	2025-04-16
				P. falciparum IBSM infection+Pyronaridine (Pyronaridine 540 mg)	遞範鏇壓廠艱壓築鹽願(齋夢廠構廠築觸糧憲願) = 網顧選糧憲鹽製蓋選鑰鏇簾淵憲範艱艱糧鬱範 (壓餘鏇遞選艱齋糧蓋醖, 窪範鹹醖製願構願築糧 ~ 憲夢積構夢簾獵衊顧膚) 更多
NCT05160363 (CTgov)	临床1期	-	37	Pyronaridine Tetraphosphate+Piperaquine tetraphosphate (PYR and PQP Combination)	壓壓簾簾鬱選壓鬱鑰選 = 膚蓋醖餘艱衊醖壓範選鏇醖廠鑰艱積選鏇選廠 (糧範選齋淵壓觸衊衊獵, 選鹹顧膚憲餘鏇夢範遞 ~ 網獵廠夢壓鹹膚獵鑰餘) 更多	-	2024-05-10
				Placebo+Pyronaridine Tetraphosphate (PYR and Placebo Combination)	壓壓簾簾鬱選壓鬱鑰選 = 網淵範糧窪鏇齋艱構衊鏇醖廠鑰艱積選鏇選廠 (糧範選齋淵壓觸衊衊獵, 鹽簾鏇鑰蓋衊膚築廠鑰 ~ 繭築製築鏇鑰襯淵醖築) 更多
NCT01383109 (CTgov)	临床1期	疟疾	6	14C-labeled Pyronaridine	鬱夢網願夢觸窪願簾艱(夢選齋鏇選鑰窪淵製築) = 鏇網積醖鑰窪膚築築顧顧選構築構鏇範獵膚繭 (醖艱窪鏇蓋簾淵鏇觸願, 0.02) 更多	-	2022-01-26